Some old-timers might enjoy this? Emphasis mine........
Monday February 12, 8:05 am Eastern Time
Press Release
SOURCE: ViroPharma Incorporated
ViroPharma Incorporated Announces Election of
Paul A. Brooke To Board of Directors
EXTON, Pa., Feb. 12 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM - news) announced today the election of
Paul A. Brooke to its board of directors. Mr. Brooke currently is a managing member of PMSV Holdings LLC, a partner of
MPM Bioventures and an advisory director for Morgan Stanley Dean Witter.
Mr. Brooke has spent more than 25 years in the investment industry, specializing in healthcare, and has served as an advisor on
a number of initial public offerings, corporate restructurings and mergers and acquisitions. Most recently, he was a managing
director at Tiger Management LLC. Prior to that, he was a managing director at Morgan Stanley Dean Witter and was global
head of healthcare research and strategy.
``Paul brings tremendous talent and expertise to ViroPharma's board of directors,'' said Michel de Rosen, ViroPharma's
president and chief executive officer. ``His extraordinary experience, relationships and knowledge about our industry will be an
extremely valuable asset to us as we continue to develop and implement ViroPharma's business strategy in the coming years.''
ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The
company is focused on drug development and discovery activities for viral diseases, including viral respiratory infection (VRI),
hepatitis C and RSV disease. ViroPharma's most advanced product candidate, pleconaril, is in clinical development for the
treatment of picornavirus diseases, including late stage clinical trials for VRI. ViroPharma also has product candidates in clinical
trials for the treatment of hepatitis C and RSV disease.
SOURCE: ViroPharma Incorporated |
